BACKGROUND:Calcium sulfate/poly amino acid compound materials carrying triple anti-tuberculosis drugs have been proved to have excellent slow release performance based on our preliminary studies on the physical and chemical properties and the release properties of the compound materials.OBJECTIVE:To observe the slow release performance of the calcium sulfate/poly（amino acid） compound material carrying triple anti-tuberculosis drugs in a rabbit model of spinal tuberculosis.METHODS:Twenty-four New Zealand white rabbits were used to make L; spinal tuberculosis models and divided into two groups in a random way following removal of tuberculosis lesions.Calcium sulfate/poly amino acid compound material carrying isoniazide,rifampicin,pyrazinamide or calcium sulfate/poly（amino acid） compound material with no drugs was implanted into the defect in the experimental or control group,respectively.At 2,4,6 and 8 weeks after implantation,the concentrations of isoniazid,rifampicin and pyrazinamide in the defect region,including the bone tissue,adjacent psoas major and inferior vena cava,were measured.RESULTS AND CONCLUSION:In the experimental group,the isoniazid levels in the damaged bone tissue and psoas major were kept in minimum bactericidal concentration（MBC） at 8 weeks after implantation and in the minimum inhibitory concentration（MIC） at the end of 12 weeks after implantation,while its level in the vein was kept in MBC at 2 weeks and in MIC at 8 weeks.The rifampicin levels in the bone tissue and psoas major were kept in MBC at 4 weeks after implantation and in the MIC at 8 weeks after implantation,while its level in the vein was kept MIC at 4 weeks.The pyrazinamide levels in the damaged bone tissue and psoas major were kept in MBC at 8 weeks after implantation and in the MIC until 8 weeks after implantation,while its level in the vein was kept MIC at 8 weeks.In the control group,there were no levels of isoniazid,rifampicin and pyrazinamide in the damaged bone tissue,adjacent psoas major and inferior vena cava in comparison with the baseline.These results show that isoniazid,rifampicin and pyrazinamide in the defect region can achieve sustained slow release in the rabbit model of spinal tuberculosis after implantation of the calcium sulfate/poly（amino acid） compound material carrying triple anti-tuberculosis drugs.In addition,the local drug concentration and duration in the defect region are better than those in the blood.

目的：评价高效液相色谱法同时测定异烟肼、利福平和吡嗪酰胺药物浓度的可行性。方法采用Water Spherisorb CN 5μm色谱柱；流动相为0.01mol/ml流动相为甲醇：乙腈=55：44，0.01mol/L庚烷磺酸钠（PH2.2）,流速3.0ml/min；柱箱温度30℃；检测波长220~400nm；进样体积10μl；时间范围15min。结果应用HPLC法同时测定三种药物浓度的相对回收率高于95%，绝对回收率均高于85%，且日内及日间的RSD均小于8%，符合生物样本的分析要求。结论该方法精密度高，线性关系好，同时简单、准确、灵敏度高，为指导临床用药提供了依据。

目的：探究脊柱结核在临床治疗中的手术方法，对比微创手术和传统手术治疗脊柱结核的临床效果。方法：将我院2005年6月-2010年6月收治的49例脊柱结核患者随机分成两组，A组28例采用微创手术治疗，B组21例采用传统手术进行治疗。再选取我院2005年6月-2010年6月收治的16例复杂脊柱结核患者作为C组，并采用传统手术和微创手术相结合的方式进行治疗。结果：将A组和B组患者的临床效果进行对比、分析，微创手术和传统手术相比较有创伤小，费用低，治愈率高的特点，有统计学意义（P<0.05）。在进行复杂性脊柱结核的临床治疗中，需将微创手术与传统开放手术相结合，能更好的帮助患者达到治愈，恢复健康。结论：微创手术方法在治疗脊柱结核的过程中，表现出较为明显的优势，是脊柱结核患者进行治疗方案选择的首选。在治疗复杂性脊柱结核过程中，在采取传统开放性手术的基础上，再采用微创手术加以辅助，从而能使患者得到康复。

Objectives: To observe the control release of complex of isoniazid,rifampicin,pyrazinamide triple anti-tuberculosis drugs calcium sulfate/amino acid polymer artificial bone in rats.Methods: 80 SD rats with the age of 6-7 weeks,were randomly divided into the experimental group and the control group,the experimental group(n=40) was implanted with triple anti-tuberculosis drugs bone in sacral spinal muscular;while the control group(n=40) was implanted with blank boneonly.1 day,3 days,1 week,2 weeks,4 weeks,6 weeks,8 weeks,12 weeks after transplantation,5 rats in each group were killed,high performance liquid chromatography assay rats were used to test the drug concentration in sample tissue and blood,HE stainings of rat liver and kidney were used for histological tests.Results: The triple anti-tuberculosis drugs bone in soft tissue of 1cm surrounding tissue after 1 day,3 days,1 week,2 weeks,4 weeks,6 weeks,8 weeks,12 weeks days meassured by High Performance Liquid Chromatography isoniazid was 4.09 ±0.56μg/ml,2.45 ± 1.33μg/ml,2.12±1.56μg/ml,1.58±4.12μg/ml,2.09±2.35μg/ml,2.31±1.44μg/ml,4.26±2.17μg/ml,3.79± 0.49μg/ml respectively;the rifampin was 4.02 ±1.14μg/ml,1.90±0.11μg/ml,1.88±0.90μg/ml,0.79±1.08μg/ml,0.86±0.44μg/ml,0.89±0.98μg/ml,3.92±1.09μg/ml,3.57±0.22μg/ml;the pyrazinamide was 460.87±1.41μg/ml,440.91 ±1.69μg/ml,430.21 ±0.86μg/ml,340.73 ±1.45μg/ml,320.85 ±2.0μg/ml 270.61 ±1.0μg/ml,230.38 ± 0.48μg/ml;the concentration in tissue 12 weeks later,reached 10 times the minimum inhibitory concentration.The average concentration of three drugs in venous blood were 2.79μg/ml,2.02μg/ml,4.38μg/ml respectively;histopathology showed no liver and kidney damage.Conclusions: The complex of triple anti-tuberculosis drugs calcium sulfate/amino acid polymer artificial bone can reach control release in vivo,meanwhile it is of no adverse reaction to liver and kidney tissue.